Real-world use of once-weekly semaglutide in Thai patients with type 2 diabetes mellitus: A retrospective monocentric study in Bangkok

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20211014001

Enrollment

Registered

2021-10-14

Start date

2022-01-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary (change in A1C) and secondary (including change in body weight, glycemic and weight-loss target achievement) endpoints were assessed between baseline and at the last follow-up visits after semaglutide treatment. Semaglutide Type 2 Diabetes Mellitus Real-World Data Thai patients

Interventions

Patients who previously received other GLP1 receptor agonist before initiating semaglutide,Patients who never received other GLP1 receptor agonist before initiating semaglutide

Treatment,Treatment

Experienced GLP1 receptor agonist,Naive GLP1 receptor agonist

Eligibility

Sex/Gender

All

Age

16 Years to No maximum

Inclusion criteria

Inclusion criteria: Thai patients with T2DM who initiated semaglutide for at least 1 month between 2020 and 2021 at Theptarin Hospital, Bangkok, Thailand

Exclusion criteria

Exclusion criteria: Non-Thai ethnicity Non-T2DM Use semaglutide less than 1 month

Design outcomes

Primary

Measure	Time frame
Changes in A1C from baseline to the last visit Last visit Mean changes	—

Secondary

Measure	Time frame
Proportion of patients reaching both A1C target less than 7.0% and a 5% weight loss Last visit Proportion	—

Countries

Thailand

Contacts

Public ContactYOTSAPON THEWJITCHAROEN

Theptarin Hospital

yotsapon_th@theptarin.com023487000

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026